Literature DB >> 23086451

Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key.

David B Stewart1, Arthur Berg, John Hegarty.   

Abstract

BACKGROUND: Recurrent Clostridium difficile colitis is common, yet the ability to predict recurrence is poorly developed.
METHODS: Patients ≥18 years of age treated at our institution for C. difficile of any severity were consecutively enrolled. C. difficile colitis was defined as symptoms of colitis with a positive PCR stool test. Each bacterial isolate was studied for virulence factors: tcdC mutations via PCR; the presence of genes for toxins A, B, and binary toxin using restriction fragment length polymorphism; and identification of ribotype 027 by PCR. Chi-squared tests, t tests, and logistic and linear regression were used to determine which virulence factors predicted recurrence.
RESULTS: Sixty-nine patients (male, 57 %) were studied, with a mean age of 64 ± 13 years. Twenty-one (30 %) patients were initially diagnosed as outpatients. There was no difference (p > 0.05) between virulence factors among inpatients and outpatients. The presence of a binary toxin gene was the single virulence factor independently associated with recurrence (p = 0.02). The combination of a tcdC mutation with binary toxin gene resulted in the highest odds of recurrence (OR, 5.3; 95 % CI, 3.52-6.09).
CONCLUSION: Binary toxin gene is a predictor of recurrent infection. Its presence may require longer antibiotic regimens in an effort to lower already elevated recurrence rates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23086451     DOI: 10.1007/s11605-012-2056-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  30 in total

1.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

Authors:  Sandra Dial; J A C Delaney; Alan N Barkun; Samy Suissa
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

Review 2.  Super toxins from a super bug: structure and function of Clostridium difficile toxins.

Authors:  Abigail H Davies; April K Roberts; Clifford C Shone; K Ravi Acharya
Journal:  Biochem J       Date:  2011-06-15       Impact factor: 3.857

3.  Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score.

Authors:  Yong Gil Kim; David Y Graham; Byung Ik Jang
Journal:  J Clin Gastroenterol       Date:  2012 May-Jun       Impact factor: 3.062

4.  A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors.

Authors:  Susanna Naggie; Becky A Miller; Kimberly B Zuzak; Brian W Pence; Ashley J Mayo; Bradly P Nicholson; Preeta K Kutty; L Clifford McDonald; Christopher W Woods
Journal:  Am J Med       Date:  2011-03       Impact factor: 4.965

5.  Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile.

Authors:  Simon D Goldenberg; Gary L French
Journal:  J Infect       Date:  2011-03-21       Impact factor: 6.072

6.  Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates.

Authors:  Patrizia Spigaglia; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

7.  Botulinum C2 toxin ADP-ribosylates actin and disorganizes the microfilament network in intact cells.

Authors:  K H Reuner; P Presek; C B Boschek; K Aktories
Journal:  Eur J Cell Biol       Date:  1987-02       Impact factor: 4.492

Review 8.  Clostridium difficile toxin synthesis is negatively regulated by TcdC.

Authors:  B Dupuy; R Govind; A Antunes; S Matamouros
Journal:  J Med Microbiol       Date:  2008-06       Impact factor: 2.472

9.  Clostridium perfringens iota toxin ADP-ribosylates skeletal muscle actin in Arg-177.

Authors:  J Vandekerckhove; B Schering; M Bärmann; K Aktories
Journal:  FEBS Lett       Date:  1987-12-10       Impact factor: 4.124

10.  A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates.

Authors:  M Rupnik; V Avesani; M Janc; C von Eichel-Streiber; M Delmée
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

View more
  44 in total

1.  Binary toxin and its clinical importance in Clostridium difficile infection, Belgium.

Authors:  T Pilate; J Verhaegen; M Van Ranst; V Saegeman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-08       Impact factor: 3.267

Review 2.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Recurrent Clostridium difficile infection: From colonization to cure.

Authors:  Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly
Journal:  Anaerobe       Date:  2015-04-27       Impact factor: 3.331

4.  Multilocus Variable-Number Tandem-Repeat Analysis of Clostridioides difficile Clusters in Ribotype 027 Isolates and Lack of Association with Clinical Outcomes.

Authors:  Julian R Garneau; Claire Nour Abou Chakra; Louis-Charles Fortier; Annie-Claude Labbé; Andrew E Simor; Wayne Gold; Matthew Muller; Allison McGeer; Jeff Powis; Kevin Katz; Jacques Pépin; Louis Valiquette
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

Review 5.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

6.  Evaluation of a new automated homogeneous PCR assay, GenomEra C. difficile, for rapid detection of Toxigenic Clostridium difficile in fecal specimens.

Authors:  Jari J Hirvonen; Silja Mentula; Suvi-Sirkku Kaukoranta
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

Review 7.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

8.  Clostridium difficile in the Long-Term Care Facility: Prevention and Management.

Authors:  Robin L P Jump; Curtis J Donskey
Journal:  Curr Geriatr Rep       Date:  2015-03

9.  Molecular typing and antimicrobial susceptibility testing to six antimicrobials of Clostridium difficile isolates from three Czech hospitals in Eastern Bohemia in 2011-2012.

Authors:  V Beran; E J Kuijper; C Harmanus; I M Sanders; S M van Dorp; C W Knetsch; J Janeckova; A Seidelova; L Barekova; J Tvrdik; D Chmelar; I Ciznar
Journal:  Folia Microbiol (Praha)       Date:  2017-03-22       Impact factor: 2.099

10.  Evaluation of the Cepheid Xpert C. difficile/Epi and meridian bioscience illumigene C. difficile assays for detecting Clostridium difficile ribotype 033 strains.

Authors:  Grace O Androga; Alan M McGovern; Briony Elliott; Barbara J Chang; Timothy T Perkins; Niki F Foster; Thomas V Riley
Journal:  J Clin Microbiol       Date:  2014-12-17       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.